Molecular identification and antifungal susceptibility profiles of etiologic agents of oral candidiasis among HIV-positive patients: A multicenter study

Publish Year: 1402
نوع سند: مقاله ژورنالی
زبان: English
View: 68

This Paper With 7 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_CUMM-9-2_002

تاریخ نمایه سازی: 18 آذر 1402

Abstract:

Background and Purpose: Human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) is a serious risk factor for oral candidiasis (OC). In this regard, the present study aimed to investigate the frequency of Candida species collected from the oropharyngeal cavity of HIV-positive patients and the sensitivity of these isolates to antifungal drugs.Materials and Methods: Oral samples were collected from ۱۶۹ HIV-positive patients. In addition to culture-based methods, a molecular assay via the polymerase chain reaction restriction fragment length polymorphism method was applied to identify isolates using the MspI restriction enzyme. The disk diffusion method determined the susceptibility of isolated yeasts to common antifungal drugs according to the CLSI M۴۴-A۲ protocol.Results: In total, ۸۱ participants (۴۷.۹۲%) were positive for OC, and Candida albicans was the most prevalent yeast (۵۳.۹۸%). The median age of patients was ۳۶ years old (IQR=۱۰.۵; ۱۷-۵۹), and it was found that women are ۲۷% more susceptible to HIVassociated OC (OR=۱.۲۶۸; ۹۵% CI: ۰.۶۸۵-۲.۳۴۸). Patients who received antifungal therapy had a ۹۷.۳% reduced chance for OC (OR: ۰.۰۲۷; ۹۵% CI: ۰.۰۰۸-۰.۰۹۱; P-value: ۰.۰۰۰). Antifungal therapy reduced the risk of OC by ۹۷.۳% (OR=۰.۰۲۷; ۹۵% CI=۰.۰۰۸- ۰.۰۹۱; P=۰.۰۰۰), and antiretroviral therapy decreased the chance of OC ۴.۴۲ times (OR=۴.۴۲۳; ۹۵% CI=۱.۶۹۷-۱۱.۵۲۸; P=۰.۰۰۲). The resistance rates for antifungals, namely fluconazole, ketoconazole, itraconazole, amphotericin B, and nystatin were ۱۵.۹۳%,۸.۸۵%, ۷.۹۶%, ۵.۳۱%, and ۴.۴۲%, respectively.Conclusion: Although several decades have passed since the emergence of HIV/AIDS,little information is available about fungal colonization and infections in this population. Further investigations are suggested using novel and reference molecular identification methods, such as matrix-assisted laser desorption ionization time-of-flight mass spectrometry and sequencing, respectively. In addition, more reliable methods for antifungal susceptibility testing are recommended.

Authors

Hamid Morovati

Department of Medical Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Malihe Jokari

Department of Medical Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Saba Eslami

Central Research Laboratory, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Kamiar Zomorodian

Department of Medical Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Katayoun Taeri

Behavioral Disease Council Center, Isfahan University of Medical Sciences, Isfahan, Iran

Nesa Khalaf

Department of Medical Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Hossein Khodadadi

Department of Medical Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Suleyman G, Alangaden GJ. Nosocomial fungal infections: epidemiology, infection control, ...
  • Armstrong-James D, Meintjes G, Brown GD. A neglected epidemic: fungal ...
  • Bongomin F, Gago S, Oladele RO, Denning DW. Global and ...
  • Moosazadeh M, Shafaroudi AM, Gorji NE, Barzegari S, Nasiri P. ...
  • Taverne-Ghadwal L, Kuhns M, Buhl T, Schulze MH, Mbaitolum WJ, ...
  • Erfaninejad M, Mahmoudabadi AZ, Maraghi E, Hashemzadeh M, Fatahinia M. ...
  • Patil S, Majumdar B, Sarode SC, Sarode GS, Awan KH. ...
  • Awoyeni A, Olaniran O, Odetoyin B, Hassan-Olajokun R, Olopade B, ...
  • Seminario AL, Kemoli A, Benki‐Nugent S, Chebet D, Gomez L, ...
  • Araújo JF, Oliveira AE, Carvalho HL, Roma FR, Lopes FF. ...
  • Indrastiti RK, Wardhany II, Soegyanto AI. Oral manifestations of HIV: ...
  • Barantsevich N, Barantsevich E. Diagnosis and treatment of invasive candidiasis. ...
  • Neppelenbroek K, Seó R, Urban V, Silva S, Dovigo L, ...
  • Zeng BS, Zeng BY, Hung CM, Chen TY, Wu YC, ...
  • Murphy SE, Bicanic T. Drug resistance and novel therapeutic approaches ...
  • Berkow EL, Lockhart SR. Fluconazole resistance in Candida species: a ...
  • Cornely O, Bassetti M, Calandra T, Garbino J, Kullberg B, ...
  • Lõoke M, Kristjuhan K, Kristjuhan A. Extraction of genomic DNA ...
  • Ashraf MJ, Kord M, Morovati H, Ansari S, Shekarkhar G, ...
  • Mirhendi H, Makimura K, Khoramizadeh M, Yamaguchi H. A one-enzyme ...
  • Arendrup MC, Park S, Brown S, Pfaller M, Perlin DS. ...
  • Cannon RD. Oral fungal infections: past, present, and future. Front ...
  • Katz J. Prevalence of candidiasis and oral candidiasis in COVID-۱۹ ...
  • Rafat Z, Sasani E, Salimi Y, Hajimohammadi S, Shenagari M, ...
  • Pour AH, Salari S, Almani PGN. Oropharyngeal candidiasis in HIV/AIDS ...
  • Khedri S, Santos A, Roudbary M, Hadighi R, Falahati M, ...
  • Du X, Xiong H, Yang Y, Yan J, Zhu S, ...
  • Ambe NF, Longdoh NA, Tebid P, Bobga TP, Nkfusai CN, ...
  • Goulart LS, Souza WWR, Vieira CA, Lima JS, Olinda RA, ...
  • Rajadurai SG, Maharajan MK, Veettil SK, Gopinath D. Comparative efficacy ...
  • نمایش کامل مراجع